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Abstract 
Introduction: At present, the issue of gastric mucosal damage, induced by the use of non-
steroidal anti-inflammatory drugs, remains unresolved.  
Objectives: The development of new methods of prevention of NSAID-gastropathies with 
oral coursework use of taurine and procaine, as well as the study of cellular mechanisms 
of the damaging effect of diclofenac sodium and Ketorolac tromethamine. 
Methods: The methodological approach was based on a range of theoretical, 
pharmacological, histological, statistical, biophysical methods. 
Results and discussion: Diclofenac sodium and ketorolac tromethamine, being in direct 
contact with cell membranes, cause a change in the structural and functional properties that 
present in the defect formation. This resulted in a decrease in the acid and hypo-osmotic 
resistance of model cells due to the broken or weakened bonds stabilizing the proteins 
molecules in membrane (which is associated with the dissociation of NH+-groups of the 
imidazole ring of histidine, the terminal α-amino groups (not less than 10.5% relative to 
the control), sulfhydryl groups of cysteine, phenolic groups of tyrosine, ε-amino groups of 
lysine (not less than 8.7%)). In experiments in vitro and in vivo procaine reduces the 
damaging effect of Ketorolac trometamina 28% and 19.7%, respectively, the formation of 
hidden defects reduced by 69% when taurine cellular damage was reduced by 54% and 
19.7% of the latent defects is less than 74%.  
Conclusion: Prophylactic intragastric administration of procaine or taurine for 7 days 
before ketorolac tromethamine administration significantly reduces the amount of erosive 
and ulcerative defects (87% and 90%, respectively). 
Keywords: Procaine, taurine, nonsteroidal anti-inflammatory drugs, membrane damage, 
prophylaxis, NSAID-gastropathy. 
 
Introduction 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are widely used in medical practice [1, 
2, 3]. However, the issue of tolerability and safety 
of NSAIDs is particularly urgent [1, 4]. Non-
steroidal anti-inflammatory drug gastropathy 
(NSAID-gastropathy) is a specific syndrome, 
mainly presented by the gastric mucosal lesions 
with the development of erythema, erosions 
and/or ulcers, and is recognized as one of the most 
common serious complications of NSAID 
therapy. Currently, research is being conducted to 
identify unknown mechanisms of NSAID-
gastropathy and to develop new drugs for the 
treatment and prevention of complications [5, 6]. 
To prevent and treat NSAID-dependent 
gastropathies, proton pump inhibitors, histamine 
H2-receptor antagonists, antacids, mechanical 
protectors for the erosive-ulcerative lesion, as 
well as new drugs, e.g. rebamipide 
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gastroprotector – synthetic analogue of 
prostaglandin E2 – are used [7, 8]. However, 
histamine H2-receptor inhibitors, local bismuth 
preparations and antacids have been established 
to be ineffective for the treatment and prevention 
of gastric ulcers in patients taking non-steroidal 
anti-inflammatory drugs for a long time [9, 10]. 
Of all these drugs, proton pump inhibitors are 
considered to be the most effective. However, their 
efficiency is reduced by localization of lesions in the 
gastric mucosa, prolonged use of NSAIDs and the 
absence of H. pylori [11]. In addition, long-term use 
of drugs reducing the acidity of gastric juice 
(histamine H2-receptor blockers, proton pump 
inhibitors, antacids) increases intragastric pH and is 
capable of causing digestion disorders, which is 
manifested by the clinical picture of dyspeptic 
syndrome. On the one hand, a prolonged increase in 
pH significantly weakens the barrier to pathogenic 
and potentially pathogenic flora entering the 
gastrointestinal tract. On the other hand, the 
persistent suppression of gastric acid secretion 
causes hypergastrinemia which is fraught with 
development of dis- and metaplastic processes in 
the gastric epithelium (against a background of 
chronic inflammation) [5, 12]. Therefore, the 
development of new ways of preventing NSAID-
gastropathy and clarifying the mechanisms of the 
damaging effect of NSAIDs at the cellular level are 
topical issues [13, 14]. 
Materials and methods 
The drugs used in the study are Diclofenac 
(Lotus Laboratories Pvt. Ltd., India), Ketorol (Dr. 
Reddy’s Laboratories Ltd., India), procaine 
substances (No. LS-000007, 2010-01- 18 
HubeiMaxpharmIndustriesCo, China) and taurine 
(FS.2.1.0039.15; CAS: 107-35-7, CJSC "Vekton", 
Russia).  Experimental studies were conducted on 
503 white mongrel male rats with an initial weight 
of 200-250 g and 225 white mongrel mice of both 
sexes weighing 20-25 g, obtained from the vivarium 
of the Voronezh N.N. Burdenko State Medical 
University. Animals were kept in vivarium 
conditions, T = 17-24 °C, under natural light 
conditions, 50-70% humidity, and were fed with 
conventional combined fodder [15]. 
Study of the ulcerogenic effect of ketorolac 
tromethamine 
 The experiments were carried out in 
accordance with the recommendations of the 
"Guidelines for experimental (preclinical) study of 
new pharmacological substances" [16], using the 
“Biomed-1” microscope (research and production 
company Delta Trans LLC, Russia). The design of 
the study is shown in the figure (Fig. 1) 
Study of the blood coagulation system 
Coagulograms were recorded on the 
automated coagulation analyzer (model “H 334”, 
JSC "Krasnodar ZIP", Russia) [17], the design 
and doses of the experiment being similar to the 
design of the ulcerogenic experiments. 
Study of the structural and functional 
properties of erythrocyte membranes. 
Spectrophotometric method was used (“PE 5400 
VI” spectrophotometer, "Ekohim" Ltd., Russia) 
for the registration of hypo-osmotic acid 
resistance of erythrocytes placed in the hypo-
osmotic solution of sodium chloride (0.55%) [18], 
or by adding of 0,1M hydrochloric acid solution 
to 5 ml of erythrocyte suspension [19]. The main 
analyzed erythrogram indices calculated by the 
equation [18] were as follows: 1) Kmax – constant 
maximum speed of erythrocyte hemolysis 
(relative units), Gsph – relative amount of 
spherocytes (%), G120 – hemolyzed erythrocytes 
in the hypo-osmotic environment for 120 seconds 
(%). The blood of 230 white mongrel rats was 
used. The design of the experiments is shown in 
the figure (Fig.1). 
Study of the optical properties of proteins 
 Spectrophotometric method was used (“PE 
5400 VI” spectrophotometer, "Ekohim" Ltd., 
Russia) [20], oxyhemoglobin solutions were 
prepared of the blood of 95 white mongrel male 
rats, the concentration was monitored 
spectrophotometrically (D = 0.8). The design of 
the study is shown in the figure (Fig. 1).  
Study of alkaline buffer capacity of proteins 
with acid-base titration. The degree of modifier 
effect to physicochemical properties of the protein 
was evaluated according to the change in the 
alkaline buffer capacity of aqueous solutions of the 
protein using hemoglobin as an example. 
Oxyhemoglobin solutions at a concentration of 5 • 
10-5 mol/L were used. Oxyhemoglobin solutions 
were made by osmotic hemolysis of red blood cells 
of white mongrel male rats weighing 180-240 g  
(n = 95). The amount of hemoglobin was monitored 
spectrophotometrically.  
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Fig. 1. The study design 
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The kinetics of the buffering capacity of 
hemoglobin was evaluated by means of “pH-150M” 
pH-metering device (RUE "Gomel Plant of 
Measuring Devices", Belarus), “TS-1/80SPU” 
electric dry-air thermostat, JSC "Smolenskoye 
SKTB SPU", Russia), “OPN-8” laboratory medical 
centrifuge (“TNK Dostan”, OJSC, Kyrgyz 
Republic), “MS-01” magnetic stirrer, “ELMI” Ltd., 
Latvia), titrating a solution of intact or modified 
hemoglobin 0,1 M NaOH in the pH range 3.0-11.0 
[21]. Substance concentrations in in vitro 
experiments, use pattern and dosing regimen in in 
vivo experiments, as well as the number of animal 
series correspond to the method of studying the 
structural and functional properties of erythrocyte 
membranes. 
Pathomorphological studies 
The number of series and animals in series, 
medical regimen, dosage regimen of procaine, 
taurine, ketorolac tromethamine are similar to the 
method used for studying ulcerogenic effects [16]. 
Internal organs (stomach, liver, kidneys) were taken 
to prepare histological preparations [22]. 
Reliability of the results obtained is based on 
the use of modern methods, instruments and 
devices, a sufficient number of experiments 
performed, representativeness of sample (728 
specimens of laboratory animals, no less than 6 
specimens per group) and adequate statistical 
processing of the information obtained using 
parametric criteria (Student's t-test) and 
nonparametric criteria (the Wilcoxon test and the 
Mann-Whitney U test). 
Results 
Study of the analgesic activity. The 
calculated effective dose (ED50) values required 
for further studies were 4.5 mg/kg for diclofenac 
sodium and 0.375 mg/kg for ketorolac 
tromethamine, according to abdominal 
constriction test. 
Study of the efficacy of procaine and taurine 
for the prevention of ketorolac tromethamine 
ulcerogenic effect 
 It has been established that prophylactic 
intragastric administration of procaine at a dose of 
1.07 mg/kg and taurine at a dose of 7.14 mg/kg 
for 7 days before administration of ketorolac 
tromethamine at an ulcerogenic dose UD50  
(0.94 mg/kg) decreased the number of erosive 
ulcerative lesions of the stomach by 87.4% and 
89.96%, respectively, compared to ketorolac 
tromethamine administered alone. Omeprazole 
provided no cases of ulcers in animals, but the 
long-term use of  proton pump inhibitors (PPI) is 
characterized by a number of side effects and 
firstly by digestive disorders, which was 
confirmed by a decrease in feed intake and a 
consequent decrease in body weight by 10% in 
animals of this experimental group. 
Pathomorphological studies 
 It has been established that the use of 
ketorolac tromethamine at a UD50 dose (0.94 
mg/kg) after a 16-hour fasting was accompanied 
by multiple small necrotic foci in the apical part 
of the gastric glands, as well as foci of ulceration, 
destruction with deeper damage to the gastric 
mucosa and a decrease in the mucous layer 
density (increased amount of thinned areas). 
These changes may be induced by the main 
mechanism of ketorolac tromethamine action 
(blocking COX isoforms) and direct damage to 
the cell membranes of gastric mucosa. 
Table 1 
Study of the efficiency of procaine and taurine for the prevention of ketorolac tromethamine 
ulcerogenic effects (M±m) 
 
Animal group 
Number of animals in 
the group 
Number of gastric mucosal  
ulcers, pcs. 
Control 10 0 
Ketorolac tromethamine 0.94 mg/kg 10 13.25±6.67* 
Ketorolac tromethamine 0.94 mg/kg + 
Procaine 1.07 mg/kg 
10 
1.67±1.5* 
Ketorolac tromethamine 0.94 mg/kg 
+Taurine 7.14 mg/kg 
10 
1.33±1.03* 
Omeprazole 111.43 mg/kg 10 0 
Note: * – the differences are statistically significant at р<0.05 
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After the prophylactic taurine administration 
to animals at a dose of 7.14 mg/kg or procaine 
(1.07 mg/kg) before ketorolac tromethamine 
administration at a dose of UD50, the gastric 
mucosa was better preserved and the defects were 
much less pronounced; there were insignificant 
isolated foci of desquamation of the apical part of 
the glands and dystrophy of the mucous 
membrane covering layer. Along with this, the 
gland mucous layer density compared to 
ketorolac tromethamine alone increased and 
approached the control value. Structural 
organization of the liver and kidneys in all groups 
remains within the norm. 
 
                    
 
Fig. 2. Histoarchitecture of the gastric mucosa in the prevention of ketorolac tromethamine-induced 
NSAID-gastropathy by taurine and procaine 
Note: A) control; B) ketorolac tromethamine; С) ketorolac tromethamine + taurine; D) ketorolac tromethamine + 
procaine (Color. gem-eosin. Magnification, appr. 7, v. 40) 
 
Study of structural and functional 
properties of membranes for erythrocytes 
modified with sodium diclofenac and ketorolac 
tromethamine. Review of Kmax for acid 
hemolysis (Table 2, 3), which characterizes the 
hemolytic sensitivity of mid-resistant 
erythrocytes, showed that sodium diclofenac at 
concentrations of 0.78•10-5; 1.57•10-5; 3.14•10-5 
mol/L and ketorolac tromethamine at 
concentrations of 6.21•10-7; 1.24•10-6; 2,48•10-6 
mol/L with incubation for 0, 15, 30, 60, 120 and 240 
minutes in experiments in vitro results in dose-
dependent increase (compared to the control) in the 
amount of erythrocytes concurrently entering the 
hemolysis stage.  Thereafter they increase the 
hemolysis rate by 56.6% -1226.9% with the use of 
diclofenac sodium and by 27% -132% when 
introducing ketorolac tromethamine into the 
erythrocyte suspension, as a result of the formation 
of structural defects in cell membranes. Along with 
this, erythrocyte subpopulations have been 
conditionally classified under low-mid-high- and 
super-resistant subpopulations, which is represented 
by a change of modification processes for a 
destructive process, manifested in the presence of 
maximal and minimal values of Kmax. Increase in 
the concentration of sodium diclofenac and 
ketorolac tromethamine shortens the period of 
modification and subsequent destruction of 
erythrocyte membranes. This action of diclofenac 
sodium and ketorolac tromethamine is obviously 
associated with chemical binding to protein-lipid 
complexes, which leads to the membrane damage 
and a decrease in the H + ion permeability threshold 
compared to the control value. 
The proportion of spherocytes (Gsph index 
reflecting the structural and functional properties of 
a low-resistant population of erythrocytes) modified 
by diclofenac sodium at concentrations of 0.78 • 10-
5; 1.57 • 10-5; 3.14 • 10-5 mol/L and ketorolac 
tromethamine at concentrations of 6.21 • 10-7; 1.24 
• 10-6; 2.48 • 10-6 mol/L was lower than those in the 
control group by 100% -14.7% and 100% -17.6%, 
respectively, depending on the concentration and 
incubation time (see tables 2, 3). This indicates that 
the low-resistant population of erythrocytes also 
shows greater sensitivity to the action of these 
modifiers. However, in separate incubation 
regimens, the proportion of spherocytes exceeds the 
control value by 33% -140%, and in half the cases, 
when erythrocytes were modified by ketorolac 
trometamine, spherocytosis was not recorded. This 
points to a conditional division of low-resistant 
erythrocytes into subpopulations according to their 
resistance to acid hemolytic. 
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Table 2 
Indices of acid and hypo-osmotic hemolysis of erythrocytes modified with sodium diclofenac depending  
on incubation time (M±m) 
 
Concentrations,  
mol/L 
Кmax of acid hemolysis 
Incubation time, min 
0 15 30 60 120 240 
Control 0.709±0.07 0.71±0.08 0.705±0.06 0.704±0.13 0.703±0.13 0.717±0.13 
0.78·10-5 1.11±0.1* 1.88±0.07* 2.25±0.11* 3.27±0.13* 1.80±0.2* 1.483±0.25* 
1.57·10-5 2.747±0.1* 3.08±0.08* 4.71±0.13* 4.35±0. 2* 3.73±0.13* 3.487±0.19* 
3.14·10-5 3.732±0.1* 6.314±0. 1* 5.671±0.2* 5.15±0.25* 5.15±0.38* 9.514±0.5* 
Gsph (%) of acid hemolysis 
Control 4.0±0.32 3.4±0.2 3.6±0.22 3.8±0.2 3.9±0.25 3.6±0.45 
0.78·10-5 7.6±0.35* 2.6±0.2* 2.3±0.19* 1.8±0.32* 5.2±0.26* 3.6±0.45 
1.57·10-5 0* 0.3±0.06* 0.6±0.13* 1.9±0.32* 2.5±0.25* 0.8±0.13* 
3.14·10-5 0* 2.9±0.13* 2.9±0.13* 3.1±0.1* 1.7±0.13* 2.6±0.19* 
Kmax (relative units) of hypo-osmotic hemolysis 
Control 4.7±0.27 4.7±0.36 5.1±0.3 4.7±0.36 5.1±0.34 4.7±0.36 
0.78·10-5 5.1±0.36* 7.1±0.4** 9.5±0.55** 8.1±0.45** 8.1±0.45** 8.1±0.45** 
1.57·10-5 7.1±0.19** 9.5±1.0** 9.5±0.55** 8.2±0.4** 8.1±0.45** 8.1±0.45** 
3.14·10-5 7.1±0.19** 14.3±1.2** 9.5±0.55** 14.3±1.25** 14.3±1.2** 19.1±1.7** 
G120 (%) of hypo-osmotic hemolysis  
Control 11.64±1.5 11.64±1.5 11.66±1.9 11.64±2.1 11.66±1.95 11.64±1.5 
0.78·10-5 25.11±2.3** 28.64±2.5** 32.01±3.1** 33.0±3.1** 33.5±3.2** 33.7±3.5** 
1.57·10-5 29.21±2.1** 33.13±3.1** 34.25±3.5** 34.42±3.5** 36.45±3.7** 40.9±3.8** 
3.14·10-5 34.67±2.5** 35.48±2.5** 37.41±3.2** 41.05±3.0** 43.52±3.5** 48.9±4.0** 
Note: ** – the differences are statistically significant at  p <0.001, * – the differences are statistically significant at p <0.05 
Table 3 
Indices of acid and hypo-osmotic hemolysis of erythrocytes modified with ketorolac tromethamine 
depending on incubation time (M±m) 
 
Concentrations, 
mol/L 
 Incubation time, min 
0 15 30 60 120 240 
 Кmax of acid hemolysis, relative units 
Control 3.3±0.16 2.2±0.15 2.4±0.15 3.5±0.17 3.7±0.18 3.7±0.18 
6.21·10-7 1.9±0.1** 5.1±0.2** 4.3±0.2** 6.3±0.3** 5.1±0.2** 5.8±0.3** 
1.24·10-6 2.5±0.1** 4.7±0.2** 4.3±0.2** 7.1±0.3** 5.1±0.3** 6.3±0.3** 
2.48·10-6 2.6±0.1** 5.1±0.2** 4.3±0.2** 5.8±0.3** 4.7±0.3** 2.9±0.2** 
Gsph of acid hemolysis, % 
Control -1.5±0.1 -2.7±0.2 -3.4±0.2 -3.6±0.2 -2.7±0.14 -1.4±0.11 
6.21·10-7 0** 0.6±0.03** 1.2±0.1** 0.3±0.01** 1.0±0.1** 1.7±0.1** 
1.24·10-6 
-2.0±0.1** 0.2±0.1** -0.5±0.15** 0.8±0.1** 
-
0.6±0.03** 0.8±0.05** 
2.48·10-6 -3.6±0.2** -3.6±0.2** -2.8±0.14** -1.7±0.1** -2.0±0.1** -2.8±0.2** 
Кmax of hypo-osmotic hemolysis, relative units 
Control 6.314±0.32 6.314±0.32 6.314±0.35 7.115±0.36 7.115±0.36 7.115±0.4 
6.21·10-7 7.115±0.4** 11.43±0.6** 9.5±0.5** 7.115±0.41 11.43±0.5** 11.4±0.6** 
1.24·10-6 9.514±0.5** 11.43±0.5** 9.514±0.5** 8.1±0.5** 9.5±0.48** 9.5±0.48** 
2.48·10-6 11.43±0.5** 11.43±0.5** 9.514±0.5** 11.43±0.5** 9.514±0.4** 8.144±0.4** 
G120 (%) of hypo-osmotic hemolysis 
Control 24.2±2.1 26.0±1.4 27.0±1.3 29.0±1.51 29.0±2.0 29.0±1.7 
6.21·10-7 24.4±1.5 29.8±1.5** 27.0±1.4 21.8±1.8** 22.8±1.1** 25.1±1.3** 
1.24·10-6 29.7±1.5** 38.4±2.0** 34.6±1.8** 32.4±1.6* 27.0±1.4 31.0±1.6 
2.48·10-6 39.4±2.5** 37.5±1.9** 37.3±1.9** 35.5±2.0** 31.4±1.8 31.3±1.8** 
Note: ** – the differences are statistically significant at p <0.001, * – the differences are statistically  significant at  
p <0.05 
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Analysis of the kinetics of erythrocyte hypo-
osmotic hemolysis (in in vitro experiments) 
showed that addition of diclofenac sodium at 
concentrations of 0.78 • 10-5; 1.57 • 10-5;  
3.14 • 10-5 mol/L and ketorolac tromethamine at 
concentrations of 6.21 • 10-7; 1.24 • 10-6;  
2.48 • 10-6 mol/L to the incubation medium 
increases dose-dependently the number of latent 
defects of erythrocyte membranes, which is 
confirmed by an increase in the values of Kmax for 
hypo-osmotic hemolysis by 8.5% -306.4% and 
12.7% -81%, respectively, compared to the 
control (Tables 1, 2). This is confirmed by a dose-
dependent increase in the proportion of 
hemolyzed erythrocytes by 115.7% -320.8% 
compared to the control using diclofenac sodium 
at the concentrations specified when observed for 
120 seconds of the experiment (G120) (Table 1). 
At concentrations of 1.24 • 10-6; 2.48 • 10-6 mol/L 
G120 values (Table 2) exceed the control level by 
8% -62.8%, and at ketorolac tromethamine 
concentrations of 6.21 • 10-7 mol/L they either 
exceed the control level by 14.6% or they are less 
than the control level up to 24.8%. This indicates 
the manifestation of modifying reactions for the 
more resistant red blood cells compared to the 
control. As incubation time and/or dose increase, 
modifying reactions are replaced by the 
prevalence of destructive processes. These 
changes probably indicate the interaction of 
sodium diclofenac and ketorolac tromethamine 
with spectrin-actin and lipo-stromatin complexes, 
i.e. the cytoskeleton of the membrane, which 
presents in a decrease in the erythrocyte hypo-
osmotic resistance by means of membrane 
destruction and increased permeability for water 
and ions. 
Study of the structural and functional 
properties of membranes for erythrocyte 
modified with procaine and taurine 
The values of the main indices of acid and 
hypo-osmotic hemolysis erythrograms are 
presented in Tables 4-5. The amount (%) of 
erythrocytes modified with procaine at 
concentrations of 4.9•10-6; 1 • 10-5; 2.01 • 10-5 
mol/L, simultaneously entering the stage of 
proper acid hemolysis (Kmax) in all cases is less 
than the control by 6.6% -38.5% or equal to it 
(Table 3). Analysis of spherocytosis for 
erythrocytes, modified with procaine at 
concentrations of 4.9 • 10-6; 1 • 10-5; 2.01 • 10-5 
mol/L with incubation time 0 to 240 minutes, 
showed that the spherocyte amount (Gsph) in the 
vast majority of cases is more than the control by 
15-170%, but in a number of experiments it is 
equal to or less than the control (Table 3).  
 
Table 4 
Indices of acid and hypo-osmotic hemolysis for erythrocytes modified by procaine depending  
on incubation time (M±m) 
 
Concentrations, 
mol/L 
Кmax of acid hemolysis, relative units 
Incubation time, min. 
0 15 30 60 120 240 
Control 3.7±0.19 3.7±0.27 3.7±0.21 3.5±0.18 3.5±0.19 3.5±0.19 
2.01·10-5 3.7±0.2 2.7±0.15** 2.7±0.18** 3.1±0.16* 2.9±0.16* 2.9±0.15* 
1.0·10-5 3.5±0.18 2.7±0.14** 2.7±0.15** 2.6±0.2** 2.5±0.13** 2.5±0.15** 
4.9·10-6 3.5±0.21** 2.7±0.2** 2.4±0.15** 2.1±0.1** 2.6±0.22** 2.6±0.15** 
Gsph of acid hemolysis, % 
Control -1.9±0.12 -1.7±0.1 -1.1±0.11 -1.2±0.1 -1.0±0.09 -1.0±0.1 
2.01·10-5 -2.6±0.2** -1.3±0.13* -2.0±0.1** -2.2±0.14** -4.0±0.17** -4.0±0.2** 
1.0·10-5 -2.2±0.12* -0.8±0.1** -1.4±0.1* -2.4±0.12** -3.0±0.15** -3.1±0.2** 
4.9·10-6 -1.8±0.1 -1.2±0.1** -1.6±0.12** -1.2±0.13 -2.50.13** -2.7±0.14** 
G120 (%)of hypo-osmotic hemolysis 
Control 44.1±2.5 35.4±2.1 37.1±1.9 36.6±1.6 40.4±1.9 40.4±2.1 
2.01·10-5 32.6±1.7** 40.7±2.0* 38.4±2.3 40.8±2.1* 39.3±2.0 39.1±2.0 
1.0·10-5 37.4±2.5** 40.0±2.3* 38.6±1.8 35.9±1.8* 32.8±1.6** 32.5±1.6** 
4.9·10-6 44.3±3.0 36.2±1.9 36.4±2.2 35.0±1.8 38.9±1.9 39.0±2.0 
Note: ** – the differences are statistically  significant at  p <0.001, * – the  differences are  statistically significant at p<0.05 
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Table 5 
Indices of acid and hypo-osmotic hemolysis for erythrocytes modified with taurine depending  
on incubation time (M±m) 
 
Concentration, 
mol/L 
Incubation time, min. 
0 15 30 60 120 240 
Кmax of acid hemolysis, relative units 
Control 3.732±0.21 3.732±0.19 3.732±0.18 3.732±0.18 3.732±0.2 3.732±0.18 
1.44·10-4 3.732±0.18 3.732±0.2 3.732±0.21 3.732±0.18 
2.904±0.14*
* 
2.475±0.13*
* 
7.2·10-5 3.078±0.17* 3.078±0.16* 2.605±0.14** 2.1±0.11** 2.05±0.13** 1.963±0.1** 
3.6·10-5 3.078±0.16* 3.078±0.16* 2.246±0.11** 1.963±0.11** 2.904±0.14** 2.904±0.15** 
Gsph of acid hemolysis, % 
Control -1.94±0.18 -1.70±0.17 -1.12±0.15 -1.17±0.16 -1.02±0.12 -1.02±0.12 
1.44·10-4 -2.9±0.15** -3.4±0.21** -3.4±0.17** -5.2±0.25** 
-
5.26±0.25** 
-
5.59±0.27** 
7.2·10-5 -4.4±0.27** -4.9±0.25** -3.69±0.19** 
-
5.07±0.25** 
-
6.38±0.39** 
-
6.77±0.34** 
3.6·10-5 -5.41±0.3** -5.90±0.3** -6.20±0.31** 
-
7.42±0.37** 
-
6.44±0.35** 
-
6.44±0.32** 
Кmax of hypo-osmotic hemolysis, relative units 
Control 6.3±0.31 6.314±0.32 6.314±0.29 6.314±0.43 6.314±0.35 6.314±0.27 
1.44·10-4 2.9±0.16** 3.5±0.17** 3.7±0.18** 1.4±0.1** 1.2±0.11** 3.1±0.15** 
7.2·10-5 2.9±0.14** 2.1±0.15** 1.9±0.1** 2.1±0.11** 0.7±0.1** 1.3±0.1** 
3.6·10-5 4.7±0.23** 4.0±0.24** 2.475±0.15** 1.7±0.13** 3.1±0.16** 3.7±0.15** 
G120 (%) of hypo-osmotic hemolysis 
Control 44.1±2.72 30.2±1.91 30.8±2.13 30.9±1.5 31.8±1.64 31.8±1.6 
1.44·10-4 16.4±1.5** 12.8±1.53** 14.3±0.74** 7.2±1.11** 4.3±0.56** 5.2±0.53** 
7.2·10-5 15.4±0.81** 14.0±0.77** 12.4±0.88** 9.4±0.54** 5.7±0.47** 2.7±0.14** 
3.6·10-5 15.3±0.13** 11.4±0.57** 8.7±0.45** 4.3±0.22** 4.9±0.25** 4.7±0.27** 
Note: ** – the differences are statistically significant at p <0.001, * – the differences are statistically significant at 
p<0.05 
 
At the same time, more intensive 
development of the prehemolytic stage indicates 
an increased sensitivity of the "low-resistant" 
erythrocyte population to acid hemolytics. From 
this it follows that procaine increases the 
permeability of "low-resistant" erythrocytes 
membranes for H + ions, for "mid-" and "high-
resistant" erythrocytes the use of procaine leads to 
modification, which is performed by increasing 
the barrier of permeability for H + ions.  
When using taurine at concentrations of  3.6 • 
10-5; 7.2 • 10-5; 1.44 • 10-4 mol/L, prehemolytic 
phase is within 120 seconds, while for the control 
group it is in the range of 30-60 seconds, which 
indicates a certain delay in the development of the 
phase of RBC hemolysis proper. The number of 
erythrocytes simultaneously entering the proper 
hemolysis stage (Kmax) did not exceed the control or 
was less than the control by17.5% -47.4% (Table 4). 
At the same time, the amount of spherocytes against 
the background of taurine administration exceeded 
the control by 48.5% -563.7% (Table 4). These 
changes indicate an increase in the acid resistance of 
erythrocytes, apparently due to the interaction of 
taurine with protein-lipid membrane complexes and 
its antioxidant, membrane-stabilizing action. 
Addition of procaine at concentrations of  4.9 
• 10-6; 1 • 10-5; 2.01 • 10-5 mol/L to the suspension 
of erythrocytes, in conditions of hypo-osmotic 
environment, does not affect the rate of hypo-
osmotic hemolysis, and taurine at concentrations 
of 3.6 • 10-5; 7.2 • 10-5; 1.44 • 10-4 mol/L reduces 
it by 25.5% -88.1% (Table 3, 4). However, the 
structural and functional state of erythrocytes 
more resistant to the hypo-osmotic environment 
(G120) is characterized by the dose-dependent 
interaction of procaine with the spectrin-actin and 
lipo-stromatin membrane complexes. And with 
an increase in the dose of procaine to 1.0 • 10-5 
mol/L; 2.01 • 10-5 mol/L and the incubation time, 
possibly due to the formation of a larger number 
of complexes, some degradation of the 
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cytoskeleton of erythrocyte membranes is 
observed, that is, formation of latent membrane 
defects. At the procaine concentration of 4.9 • 10-
6 mol/L, such changes were not observed and the 
amount of hemolyzed erythrocytes within 120 
seconds of the experiment did not exceed the 
control level (Table 3). In case of using taurine at 
the indicated concentrations, in all experiments, 
the G120 values were less than the control by 63% 
-91.5% (Table 4). 
Study of structural and functional 
properties of membranes for erythrocytes 
modified with ketorolac tromethamine in 
combinations with procaine and taurine 
 In experiments in vivo, animals were 
prophylactically given intragastric procaine or 
taurine at doses of 1.07 mg/kg and 7.14 mg/kg for 
7 days, and ketorolac tromethamine at a dose of 
UD50 was administered on day 8. The results are 
presented in Tables 6, 7. 
 
Table 6 
Indices of acid and hypo-osmotic hemolysis of erythrocytes modified with ketorolac tromethamine  
in combination with procaine and taurine (M±m) 
 
Group Кmax of acid hemolysis, relative units 
 
Incubation time, min. 
0 15 30 60 120 240 
Control 4.011±0.2 4.011±0.23 4.011±0.21 3.732±0.19 3.732±0.22 3.732±0.18 
Taurine + Ketorolac 
tromethamine 
4.011±0.24 4.011±0.2 3.271±0.18** 4.331±0.23* 4.331±0.21* 4.331±0.25* 
Procaine + Ketorolac 
tromethamine 
5.2±0.25** 5.2±0.25** 5.145±0.28** 5.671±0.27** 5.671±0.29** 6.314±0.32** 
Gsph of acid hemolysis, % 
Control -1.936±0.11 -1.698±0.11 -1.121±0.1 -1.166±0.12 -1.016±0.1 -1.016±0.07 
Taurine + Ketorolac 
tromethamine 
-3.7±0.19** -4.5±0.22** -4.6±0.23** -5.1±0.21** -5.7±0.25** -5.4±0.27** 
Procaine + Ketorolac 
tromethamine 
-2.2±0.11 -1.3±0.1* -1.5±0.14* -2.9±0.16** -2.56±0.13** -4.35±0.18** 
Кmax of hypo-osmotic hemolysis, relative units 
Control 5.145±0.25 4.705±0.23 4.705±0.24 4.705±0.23 4.705±0.23 4.705±0.23 
Taurine + Ketorolac 
tromethamine 
4.7±0.25 3.7±0.19** 3.7±0.2** 2.9±0.17** 3.7±0.21** 3.7±0.18** 
Procaine + Ketorolac 
tromethamine 
3.5±0.18** 4.7±0.24 5.1±0.26 5.1±0.25 5.7±0.29** 6.3±0.32** 
G120 (%)of hypo-osmotic hemolysis 
Control 22.2±1.51 22.9±1.15 21.8±1.14 23.6±1.25 23.4±1.17 22.7±1.14 
Taurine + Ketorolac 
tromethamine 
19.8±1.13 15.1±1.21** 13.0±1.43** 10.9±0.94** 9.2±1.11** 7.2±0.73** 
Procaine + Ketorolac 
tromethamine 
15.8±0.82** 11.8±1.32** 12.3±1.15** 11.4±0.87** 9.1±0.57** 9.1±0.57** 
Note: ** – the differences are statistically significant at p <0.001, * – the differences are statistically significant at 
p<0.05 
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Fig. 3. The values of Kmax (relative units) of erythrocyte acid hemolysis against the background of the use 
of ketorolac tromethamine and its combination with taurine and procaine. 
Note: control      ; taurine + ketorolac tromethamine      ; procaine + ketorolac tromethamine    ; ketorolac 
tromethamine 
 
Analysis of the combined use (in in vitro 
experiments) of taurine (7.2 x 10-5 mol/L) and 
procaine (4.9 x 10-6 mol/L) with ketorolac 
tromethamine (1.24 x 10-6 mol/L) allow us to 
conclude that procaine and, to a greater extent, 
taurine, prevent ketorolac tromethamine-induced 
damage to erythrocyte membranes. This is 
confirmed by a significant decrease in the rate of 
acid hemolysis (up to 57%) for the main mid-
resistant erythrocyte population, a significant 
increase in the amount (%) of erythrocytes that are 
simultaneously in the stage of spherulation 
(maximum by 100%), and the duration of the 
prehemolytic stage of hemolysis (maximum  
by100%) against the background of combined use 
of these modifiers compared to the use of 
ketorolac tromethamine alone. 
Table 7 
Values of Kmax, Gsph and G120 indices of acid and hypo-osmotic hemolysis against the combination of 
ketorolac with procaine and taurine in vivo (M±m) 
 
Name 
Acid hemolysis Hypo-osmotic hemolysis 
Kmax, relative units Gsph,% 
Kmax, 
relative 
units 
G120,% 
Control 4.3±0.25 -0.9±0.05 5.7±0.29 42.9±2.15 
Ketorolac tromethamine 7.1±0.35** -1.1±0.06* 19.1±0.75** 62.3±3.12** 
Ketorolac tromethamine + Taurine 5.7±0.28** -2.4±0.12** 4.3±0.27* 25.8±1.97** 
Ketorolac tromethamine + Procaine 5.7±0.31** -2.2±0.11** 5.7±0.36 30.6±2.57** 
Note: ** – the differences are statistically significant at p <0.001, * – the differences are statistically significant at p<0.05 
 
Analysis of the hypo-osmotic erythrogram 
faindings reveals that the introduction of procaine 
and taurine into the suspension of erythrocytes 
prevents the formation of latent defects induced 
by ketorolac tromethamine. This is reflected in a 
decrease in the rate of erythrocyte hypo-osmotic 
hemolysis when combined with taurine by 8.6% – 
38.3% compared to the control. In case of 
combined use of ketorolac tromethamine with 
procaine, the hemolysis rate was less than or equal 
to the control during incubation up to 30 min, and 
it increased by 9.4% -34.2% in the period of 30-
240 minutes compared to the control. When 
ketorolac tromethamine used alone, Kmax 
А А А 
А 
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exceeded the control by 14.5% -81%. Besides, 
G120 values for hypo-osmotic hemolysis against 
the combined use of procaine and taurine with 
ketorolac tromethamine with an incubation time 
of 0-240 minutes decreased by 10.8% -68.1% 
compared to the control. While for the use of 
ketorolac tromethamine alone, the G120 values 
exceeded the control by 6.9% -47.7%. 
Analysis of the results of the in vivo 
experiments (Table 6) showed that the 
preliminary intragastric administration of taurine 
(7.14 mg / kg) and procaine (1.07 mg / kg) for 7 
days reduces the damaging effect of ketorolac 
tromethamine at a UD50 level (0.94 mg kg) for a 
population of mid-resistant red blood cells under 
conditions of acid hemolysis. This is confirmed 
by the fact that the acid resistance of the main 
erythrocyte population when using ketorolac 
tromethamine at a dose of UD50 is reduced by 
64.3% relative to control, and with the preventive 
administration of taurine and procaine – by 
30.9%. At the same time, against the background 
of combined use of taurine and procaine with 
ketorolac tromethamine, the proportion of 
erythrocytes which are simultaneously at the 
stage of spherulation is increased by 115.99% and 
93.2% compared to the use of  ketorolac 
tromethamine alone. Also in both cases of 
combined use, the erythrogram fold area is 
reduced which indicates that the final level of 
hemolysis has been reached for a longer period of 
time. 
Comparing the data of hypo-osmotic 
erythrograms (in vivo), it can be concluded that 
the prophylactic use of taurine (7.14 mg / kg) and 
procaine (1.07 mg / kg) before administration of 
ketorolac tromethamine at a dose of UD50  
(0.94 mg / kg) decreases the number of latent 
defects in erythrocyte membranes, as evidenced 
by a decrease in the rate of hypo-osmotic 
hemolysis with prophylactic administration of 
taurine and procaine by 77.3% -70.3% and G120 
by 58.58% -50.9%, respectively, compared to the 
use of ketorolac tromethamine alone. 
Study of the effect of diclofenac sodium, 
ketorolac tromethamine, procaine, taurine and 
their combinations on the optical properties of 
proteins 
In experiments in vitro, diclofenac sodium 
was injected into the hemoglobin solution at 
concentrations of 0.78 × 10-5; 1.57 • 10-5; 3,14 • 
10-5 mol/L and ketorolac tromethamine  
(6.21 • 10-7, 1.24 • 10-6, 2.48 • 10-6 mol/L) against 
the background of a 30-minute incubation at 55 ° 
C promotes an increase in light absorbance, and 
hence the denaturation depth by 15.1%; 17.82%; 
42.15% and 14.35%; 19.4%; 35.65% 
respectively, compared to the control. These 
changes are evidently caused by a decrease in the 
number or weakening of intramolecular bonds 
(hydrogen bonds) that stabilize the space structure 
of the protein, which manifest themselves as a 
dose-dependent increase in the denaturation level 
under conditions of thermal incubation compared 
to the control. The introduction of procaine into 
the solution of oxyhemoglobin at concentrations 
of 4.9 • 10-6 mol/L; 1 • 10-5 mol/L; 2.01 • 10-5 
mol/L was accompanied by changes in the light 
absorbance, which nature was opposite to the 
experiments with sodium diclofenac and 
ketorolac tromethamine, which was reflected in a 
decrease in the denaturation depth by 2.95%; 
9.44% 17.6%, respectively, compared to the 
control. These changes may indicate some 
consolidation of the protein molecule under these 
conditions. A single application of taurine does 
not cause a change in the optical properties of this 
biopolymer under conditions of thermal 
incubation compared to the control. The 
combined use (in in vitro experiments) of 
procaine (4.9x10-6 mol/L) and taurine  
(7.2x10-5 mol/L) with ketorolac tromethamine 
(1.24x10-6 mol/L) demonstrated the denaturation 
depth to exceed the control by 7.43% -15.1%, 
respectively. When ketorolac was used at this 
dose alone, the light absorbance exceeded the 
control by 19.44%. This indicates a decrease in 
the denaturation depth for oxyhemoglobin under 
the influence of procaine in combination with 
ketorolac tromethamine compared to the use of 
the latter alone. The results of studying the optical 
properties of oxyhemoglobin, modified by 
ketorolac tromethamine and its combined use 
with procaine and taurine in in vivo experiments 
were fairy close to the control and showed no 
statistically reliable differences from the control, 
but a tendency to decrease the degree of 
denaturation against the background of 
preliminary use of procaine and taurine was 
observed. 
Study of the effect of sodium diclofenac, 
ketorolac tromethamine, procaine, taurine and 
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their combinations on the buffer properties of 
proteins 
In experiments in vitro, sodium diclofenac at 
concentrations of 0.78 • 10-5; 1.57 • 10-5; 3.14 • 
10-5 mol/L was found to cause conformational 
changes in the oxyhemoglobin molecule, which 
are accompanied by an increase in the buffer 
capacity of this protein due to the dissociation of 
H +. When using ketorolac tromethamine at 
concentrations of 6.21 • 10-7; 1.24 • 10-6; 2.48 • 
10-6 mol/L, a similar situation persisted, which 
was manifested by an increase in the alkaline 
buffer capacity mainly due to an increase in the 
dissociation of the NH + groups of the imidazole 
ring of histidine, terminal α-amino groups (by 
10.5%, 13.13%; 17.2%  compared to the control, 
respectively) and dissociation of sulfhydryl 
groups of cysteine, phenolic tyrosine groups, and 
ε-amino groups of lysine (by 8.7%, 11.76%, and 
13.8% compared to the control, respectively). 
The use of procaine at concentrations of 4.9 • 10-
6 mol/L; 1 • 10-5 mol/L; 2.01 • 10-5 mol/L was 
accompanied by a decrease in the buffer capacity 
of hemoglobin molecules mainly due to a 
decrease in the dissociation of the NH + groups of 
the imidazole ring of histidine, terminal α-amino 
groups (by 3.7%, 14.35%, 19.5% ) and 
dissociation of sulfhydryl groups of cysteine, 
phenolic tyrosine groups, ε-amino groups of 
lysine (by 5.7%, 7.7%, 10.8%) compared to the 
control. Hemoglobin modification with taurine 
solution at concentrations of 3.6 • 10-5; 7.2 • 10-5; 
1.44 • 10-4 mol/L was similar to the use of 
procaine (a decrease in the dissociation of NH + 
groups of the imidazole ring of histidine, terminal 
α-amino groups by 15.4%, 18.8%, 22.6% and 
sulfhydryl groups of cysteine , phenolic tyrosine 
groups, ε-amino groups of lysine by 1.9%, 4.2%, 
5.51% compared to the control, respectively). 
These indices indicate conformational changes 
caused by the use of procaine and taurine at 
various concentrations, which are accompanied 
by protein molecule consolidation and / or a 
decrease in the number of ionic groups available 
for titration, possibly due to the procaine (taurine) 
binding to the corresponding functional groups, 
which leads to a decrease in the number of 
ionogenic groups determined in the appropriate 
ranges of pH. 
In combination with in vitro (Table 8) of 
ketorolac tromethamine (1.24x10-6 mol/L) with 
procaine (4.9x10-6 mol/L) and taurine (7.2x10-5 
mol/L),  an increase in the alkaline buffer capacity 
was recorded by 5.95% and 8.3%, respectively, 
compared to the control, mainly due to an increase 
in the degree of dissociation of sulfhydryl groups 
of cysteine, phenolic tyrosine groups, and ε-
amino groups of lysine, which is less than values 
of corresponding changes for ketorolac 
tromethamine alone. Therefore, it can be assumed 
that the combined use in vitro of ketorolac 
tromethamine with procaine and taurine to some 
extent prevents conformational changes in the 
hemoglobin molecule, which manifest themselves 
as molecule unfolding and increase in the number 
of ionic groups available for titration. 
In experiments in vivo ketorolac 
tromethamine at a dose of UD50 was found to 
cause a change in the structural and functional 
properties of hemoglobin due to conformational 
transformation of the protein space structure, 
possibly due to molecule unfolding caused by 
breaking or weakening of bonds stabilizing it. 
This results in an increase in the buffer capacity, 
while procaine and taurine in these conditions in 
vivo do not affect the hemoglobin properties 
specified, however, there is a tendency to weaken 
the ketorolac tromethamine action on 
hemoglobin. 
Table 8 
Oxyhemoglobin buffer properties under the action of ketorolac tromethamine in combination with procaine 
and taurine (M±m) 
 
Name, concentration, mol/L 
рН /VNaOH intervals, µL 
3 – 5 5 – 9 9 – 11 
Control 422±8.37 101±8.22 605±19.40 
Ketorolac tromethamine 1.24·10-6 + Procaine 4.9·10-6 424±11.40 104±8.22 641±23.02* 
Ketorolac tromethamine 1.24·10-6 + Taurine 7.2·10-5 420±15.81 109±7.42 655±15.81* 
Note: * – the differences are statistically significant at p <0.05 
Study of the blood coagulation system. 
When studying the effect of ketorolac 
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tromethamine and its combined use with procaine 
and taurine on the coagulation system of blood, 
no significant changes were detected. 
Discussion 
       Long-term administration of currently used 
marketed drugs that reduce the acidity of gastric 
juice (histamine H2- receptor blockers, proton 
pump inhibitors, antacids), increase  intragastric 
pH and are capable of causing digestive disorders, 
which present in the clinical picture of dyspeptic 
syndrome. A prolonged increase in pH, on the one 
hand, significantly weakens the barrier to 
pathogenic and opportunistic flora entering the 
gastrointestinal tract. Persistent suppression of 
gastric secretion, on the other hand, causes 
hypergastrinemia, which is fraught with the 
development of dis- and metaplastic processes in 
the gastric epithelium (against the background of 
chronic inflammation) [12]. 
It is known that the enteral use of procaine in 
gastroduodenal ulcer at doses corresponding to 
the therapeutic range (0.25-0.5% solution up to 
30-50 ml 2-3 times a day) is well tolerated and is 
characterized by the absence of side effects, in 
particular, due to the fact that it poorly penetrates 
through the mucous membranes [23]. In addition, 
procaine has a local anesthetic effect, providing a 
reduction in the severity of epigastric pain. It 
should be emphasized that procaine blocks the ion 
channels of the cell membrane and does not affect 
the acidity of the gastric juice. 
Taurine is characterized by almost complete 
absence of side effects. Taurine has membrane-
protective properties, normalizes the ratio of cell 
membrane phospholipids, regulates oxidative 
processes and exhibits antioxidant properties, 
reduces the degree of apoptosis for endothelial 
cells, prevents excessive calcium release from 
cells, has a number of cardiovascular benefits, has 
cardio-radio- and hepatoprotective properties, 
participates in the conjugation of bile acids and 
prevents cholestasis, participates in the regulation 
of GABA secretion, has hypoglycemic and 
hypolipidemic properties [24, 25].  
Nevertheless, despite a number of properties 
that suggest the presence of a gastroprotective 
effect, procaine and taurine are not currently used 
in the clinical practice for the prevention of 
NSAID-induced damage to the gastric mucosa. 
New components of the mechanism of the 
NSAIDs damaging effect on cell membrane and 
gastric mucosa have been revealed for the first 
time on the example of diclofenac sodium and 
ketorolac tromethamine in effective analgesic 
doses determined experimentally (diclofenac 
sodium 2.25 mg/kg – 9 mg/kg, ketorolac 
tromethamine 0.1875 mg/kg 0.75 mg/kg). These 
components involves changed structural and 
functional properties of protein molecules, which 
leads to a decrease in acid and hypo-osmotic 
resistance of cells. It has been found that procaine 
and taurine exhibit a membrane-protective effect, 
since they increase the acid and hypo-osmotic cell 
resistance to the action of damaging factors in in 
vitro and in vivo experiments. It is observed both 
in their use alone and in their combination with 
ketorolac tromethamine. 
Conclusion 
The mechanism of the diclofenac sodium and 
ketorolac tromethamine damaging effect on the 
gastric mucosa has been clarified, and a direct 
damaging effect on cell membranes has been 
revealed. It has been established that the use of 
procaine and taurine increases the resistance of 
cell membranes in conditions of acidic and hypo-
osmotic environment, and also reduces damage to 
cell membranes caused by ketorolac 
tromethamine. The findings of the in vitro 
experiments are confirmed by in vivo 
experiments, demonstrating ability of procaine 
and taurine in their preventive administration to 
reduce the number of experimental erosive ulcers 
and changes of the gastric mucosal morphological 
structure induced by ketorolac tromethamine use. 
Obviously, the revealed efficiency of procaine in 
treating NSAID-gastropathy is associated with 
the ability to interact with membrane proteins and 
protein-lipid membrane complexes, causing 
changes in their conformation, and thereby 
changing the structural and functional properties 
of cell membranes, which leads to an increase in 
the permeability threshold for H +. The ability of 
taurine to inhibit ketorolac tromethamine-induced 
ulceration is possibly associated with its proven 
antioxidant and membrane-stabilizing properties, 
as well as the ability to normalize the ratio of 
phospholipids to cell membranes and the ratio of 
cholesterol to phospholipids. It follows that the 
prophylactic use of taurine (7.14 mg/kg) and 
procaine (1.07 mg/kg) before administration of 
ketorolac tromethamine (0.94 mg/kg) leads to an 
increase in gastric mucosal resistance. On this 
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evidence, original methods of protecting the 
gastric mucosa from the damaging effect of 
NSAIDs are proposed and consist of 7 days of 
prophylactic taurine (7.14 mg/kg) or procaine 
(1.07 mg/kg) dose. [26, 27, 28]. 
Besides, it was found that, both for the 
administration of ketorolac tromethamine alone 
and for its combined use with procaine or taurine, 
there were no changes in the structural 
organization of the liver and kidneys, the 
coagulogram findings did not differ from the 
control, indicating no hepatotoxic, nephrotoxic 
and hematotoxic effects. 
Conclusions 
1. New components of the mechanism of the 
damaging effect of sodium diclofenac and 
ketorolac tromethamine on cell membranes have 
been revealed; they influence the ability to induce 
weakening or breaking of intramolecular bonds 
stabilizing the protein molecule, which is 
associated with the dissociation of NH + groups of 
the imidazole ring of histidine, terminal α-amino 
groups (not less than by 10.5% compared to the 
control), sulfhydryl cysteine groups, tyrosine 
phenolic groups, and ε-amino groups of lysine (by 
at least 8.7%), and presents in an increase in the 
denaturation depth. 
2. Procaine and taurine in vitro increase the 
resistance of cells to the effects of damaging 
factors. This is proved by an increase in: a) acid 
resistance of red blood cells with the addition of 
procaine by no more than 38.5%; b) acid and 
hypo-osmotic resistance of erythrocytes with 
taurine use by no more than 47% and 88%, 
respectively. 
3. The experiments in vitro and in vivo have 
shown that procaine and taurine reduce the 
damage to cell membranes caused by ketorolac 
tromethamine at a concentration equivalent to 
ED50 and a dose equal to UD50: a) procaine at a 
concentration equivalent to a minimum 
therapeutic dose of 1.07 mg / kg – by 28% and 
19.7%, respectively, and reduces the formation of 
latent membrane defects by no less than 69%; b) 
taurine at a concentration equivalent to an average 
therapeutic dose of 7.14 mg / kg – by 54% and 
19.7%, respectively, and reduces the formation of 
latent defects by at least 74%; c) oral prophylactic 
procaine administration to rats at a dose of 1.07 
mg / kg and taurine at a dose of 7.14 mg / kg 
reduces the number of erosive and ulcerative 
defects caused by ketorolac tromethamine at a 
dose equal to UD50 by 87% and 90%, 
respectively, and also prevents changes in the 
gastric mucosal morphological structure 
according to the histological studies. 
4. Oral prophylactic procaine (at a dose of 
1.07 mg / kg) and taurine (7.14 mg / kg) 
administration before the damaging action of 
ketorolac tromethamine (0.94 mg / kg dose) is 
associated with no changes in the liver and kidney 
histoarchitecture, which is indicative of no 
hepato- and nephrotoxic effects. 
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